贝伐单抗的药理作用及对翼状胬肉治疗的研究进展

The Progress of Research on Main Pharmacological Actions of Bevacizumab and It′s Treatment of the Pterygium

贝伐单抗属抗肿瘤新药,以血管内皮生长因子(VEGF)为靶点,抑制VEGF活性,减少新生血管的形成,发挥抗纤维、血管增生的作用,从而限制肿瘤的生长,发挥抗肿瘤作用。眼部有许多与VEGF相关的新生血管性疾病,依据贝伐单抗具有对新生血管生成的抑制作用,近年来,许多眼科专家尝试将其用于翼状胬肉以及各种眼内、眼表新生血管性疾病的治疗,取得一定疗效,但尚属探讨领域,现对该药的药理原理及其在翼状胬肉治疗方面予以综述。

Bevacizumab is a kind of new anti-tumor drugs which can combine with the active site of VEGF especially and block the binding of VEGF to its receptors,suppress the action of VEGF,restraint the formation of new vessels and act against the tumor angiogenesis.Eye is liable to catch all kinds of VEGF-related noevascularization lesion and bevacizumab was used by the ophthalmologist to treats the lesion in recent years.Certain progress has been made in this field for investigation and it′s pharmacological effect,the treatment to pterygium is summarized in this article.